## Steve Simpson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/727875/publications.pdf

Version: 2024-02-01

147566 79541 6,054 131 31 73 citations h-index g-index papers 136 136 136 8613 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 831-841.	1.4	6
2	Higherâ€quality diet and nonâ€consumption of meat are associated with less selfâ€determined disability progression in people with multiple sclerosis: A longitudinal cohort study. European Journal of Neurology, 2022, 29, 225-236.	1.7	17
3	Attrition Within Digital Health Interventions for People With Multiple Sclerosis: Systematic Review and Meta-analysis. Journal of Medical Internet Research, 2022, 24, e27735.	2.1	15
4	Greater mastery is associated with lower depression risk in a large international cohort of people with multiple sclerosis over 2.5Âyears. Quality of Life Research, 2022, 31, 1789-1798.	1.5	0
5	Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. Multiple Sclerosis and Related Disorders, 2022, 59, 103561.	0.9	10
6	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
7	Prospective associations of better quality of the diet with improved quality of life over 7.5 years in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 60, 103710.	0.9	3
8	Undertaking specific stress-reducing activities are associated with reduced fatigue and depression, and increased mastery, in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103804.	0.9	1
9	Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 723-731.	0.9	10
10	Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination. Multiple Sclerosis Journal, 2022, 28, 1793-1807.	1.4	2
11	Integrating Genetic Structural Variations and Whole-Genome Sequencing Into Clinical Neurology. Neurology: Genetics, 2022, 8, e200005.	0.9	4
12	Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis. Multiple Sclerosis Journal, 2021, 27, 1250-1261.	1.4	6
13	Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. Multiple Sclerosis Journal, 2021, 27, 1262-1275.	1.4	20
14	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1112-1124.	1.4	10
15	Depression mediates the relationship between fatigue and mental health-related quality of life in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102620.	0.9	14
16	Assessing Lifestyle Behaviours of People Living with Neurological Conditions: A Panoramic View of Community Dwelling Australians from 2007–2018. Journal of Personalized Medicine, 2021, 11, 144.	1.1	2
17	Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibility loci. Multiple Sclerosis Journal, 2021, 27, 2141-2149.	1.4	3
18	Self-reported use of vitamin D supplements is associated with higher physical quality of life scores in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102760.	0.9	10

#	Article	IF	CITATIONS
19	Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 276-292.	<b>5.</b> 5	292
20	Identification of a Latitude Gradient in the Prevalence of Primary Biliary Cholangitis. Clinical and Translational Gastroenterology, 2021, 12, e00357.	1.3	4
21	Relationships with MS not unique to relapsing-onset phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1029-1030.	0.9	0
22	Two healthy lifestyle scores are associated with lower subsequent fatigue risk using inverse probability weightingÂin an international longitudinal cohort of people with multiple sclerosis. European Journal of Neurology, 2021, 28, 2952-2964.	1.7	6
23	100Identification of a latitude gradient in the prevalence of Primary Biliary Cholangitis in Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
24	178Depression but not physical activity mediates the fatigue-mental quality of life relationship in multiple sclerosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
25	125Clinical & demographic determinants of self-reported diet program adherence in people living with multiple sclerosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
26	1325Longitudinal epidemiology of MS in the Greater Hobart region, 1961 to 2019. International Journal of Epidemiology, 2021, 50, .	0.9	0
27	102Assessing the characteristics of health state utilities among people living with multiple sclerosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
28	1255Associations between select lifestyle behaviours and quality of life based on MS phenotype. International Journal of Epidemiology, 2021, 50, .	0.9	0
29	101Pre-onset sun exposure significantly associated with risk of primary biliary cirrhosis. International Journal of Epidemiology, 2021, 50, .	0.9	0
30	509Healthy-lifestyle-scores associated with lower subsequent fatigue risk in multiple sclerosis using inverse probability treatment weighting. International Journal of Epidemiology, 2021, 50, .	0.9	0
31	The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer's disease. Ageing Research Reviews, 2021, 70, 101402.	5.0	9
32	99Increasing prevalence of primary biliary cholangitis in Victoria, Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
33	Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. Nature Communications, 2021, 12, 5641.	5.8	46
34	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 2021, 97, e1870-e1885.	1.5	168
35	Sociodemographic and clinical characteristics of diet adherence and relationship with diet quality in an international cohort of people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103307.	0.9	6
36	Views of the Future of Partners of People with Multiple Sclerosis Who Attended a Lifestyle Modification Workshop: A Qualitative Analysis of Perspectives and Experiences. International Journal of Environmental Research and Public Health, 2021, 18, 85.	1.2	5

3

#	Article	IF	CITATIONS
37	Associations between Lifestyle Behaviors and Quality of Life Differ Based on Multiple Sclerosis Phenotype. Journal of Personalized Medicine, 2021, 11, 1218.	1.1	7
38	Developing a clinical–environmental–genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. Brain Communications, 2021, 3, fcab288.	1.5	7
39	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	0.4	3
40	Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal, 2020, 26, 411-420.	1.4	18
41	Predictors of Change in Employment Status and Associations with Quality of Life: A Prospective International Study of People with Multiple Sclerosis. Journal of Occupational Rehabilitation, 2020, 30, 105-114.	1.2	20
42	Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data. Multiple Sclerosis Journal, 2020, 26, 1315-1328.	1.4	30
43	Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1550-1559.	1.4	16
44	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 673-679.	1.4	10
45	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	1.4	10
46	Validation of O–10 MS symptom scores in the Australian multiple sclerosis longitudinal study. Multiple Sclerosis and Related Disorders, 2020, 39, 101895.	0.9	14
47	Keeping people with MS in the workforce through effective treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 6-6.	0.9	1
48	COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis Journal, 2020, 26, 1157-1162.	1.4	50
49	Perceived cognitive impairment is associated with sexual dysfunction in people with multiple sclerosis: A 2.5-year follow-up study of a large international cohort. Multiple Sclerosis and Related Disorders, 2020, 45, 102410.	0.9	8
50	Greater Engagement with Health Information Is Associated with Adoption and Maintenance of Healthy Lifestyle Behaviours in People with MS. International Journal of Environmental Research and Public Health, 2020, 17, 5935.	1.2	4
51	SF-6D health state utilities for lifestyle, sociodemographic and clinical characteristics of a large international cohort of people with multiple sclerosis. Quality of Life Research, 2020, 29, 2509-2527.	1.5	8
52	Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 994-1004.	1.4	41
53	Selfâ€reported cognitive function in a large international cohort of people with multiple sclerosis: associations with lifestyle and other factors. European Journal of Neurology, 2019, 26, 142-154.	1.7	12
54	Patientâ€reported outcomes are worse for progressiveâ€onset multiple sclerosis than relapseâ€onset multiple sclerosis, particularly early in the disease process. European Journal of Neurology, 2019, 26, 155-161.	1.7	20

#	Article	IF	CITATIONS
55	On the path together: Experiences of partners of people with multiple sclerosis of the impact of lifestyle modification on their relationship. Health and Social Care in the Community, 2019, 27, 1515-1524.	0.7	10
56	Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988176.	0.5	1
57	Systemic predictors of adverse events in a national surgical mortality audit: analysis of peerâ€review data from Australia and New Zealand Audit of Surgical Mortality. ANZ Journal of Surgery, 2019, 89, 1398-1403.	0.3	3
58	Modifiable factors associated with depression and anxiety in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 140, 204-211.	1.0	16
59	Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infectious Diseases, The, 2019, 19, 880-891.	4.6	85
60	Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1193-1200.	0.9	85
61	Associations of demographic and clinical factors with depression over 2.5-years in an international prospective cohort of people living with MS. Multiple Sclerosis and Related Disorders, 2019, 30, 165-175.	0.9	9
62	Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life. Multiple Sclerosis and Related Disorders, 2019, 30, 25-32.	0.9	2
63	Role of PCK1 gene on oil tea-induced glucose homeostasis and type 2 diabetes: an animal experiment and a case-control study. Nutrition and Metabolism, 2019, 16, 12.	1.3	9
64	Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 636-641.	0.9	14
65	Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1800-1808.	1.4	7
66	Vitamin D deficiency is an etiological factor for MS – Commentary. Multiple Sclerosis Journal, 2019, 25, 641-643.	1.4	2
67	Polymorphism in the serotonin transporter gene polymorphisms ( <i>5-HTTLPR</i> ) modifies the association between significant life events and depression in people with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 848-855.	1.4	6
68	Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technology Assessment, 2019, 23, 1-44.	1.3	230
69	The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults. Multiple Sclerosis and Related Disorders, 2018, 19, 161-165.	0.9	15
70	Vitamin D status is associated with executive function a decade later: Data from the Women's Healthy Ageing Project. Maturitas, 2018, 107, 56-62.	1.0	28
71	Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis. Neurological Sciences, 2018, 39, 297-304.	0.9	19
72	Longitudinal Associations of Modifiable Lifestyle Factors With Positive Depression-Screen Over 2.5-Years in an International Cohort of People Living With Multiple Sclerosis. Frontiers in Psychiatry, 2018, 9, 526.	1.3	23

#	Article	IF	Citations
73	Longitudinal Associations of the Healthy Lifestyle Index Score With Quality of Life in People With Multiple Sclerosis: A Prospective Cohort Study. Frontiers in Neurology, 2018, 9, 874.	1.1	16
74	Health Outcomes and Lifestyle in a Sample of People With Multiple Sclerosis (HOLISM): Longitudinal and Validation Cohorts. Frontiers in Neurology, 2018, 9, 1074.	1.1	25
75	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. Frontiers in Neurology, 2018, 9, 16.	1.1	30
76	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. Frontiers in Neurology, 2018, 9, 418.	1,1	8
77	Oil tea improves glucose and lipid levels and alters gut microbiota in type 2 diabetic mice. Nutrition Research, 2018, 57, 67-77.	1.3	31
78	Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1200-1207.	0.9	41
79	The Role of Vitamin D in Multiple Sclerosis: Biology and Biochemistry, Epidemiology and Potential Roles in Treatment. Medicinal Chemistry, 2018, 14, 129-143.	0.7	18
80	Response to Attarian regarding article. Acta Neurologica Scandinavica, 2017, 135, 382-382.	1.0	0
81	Sexuality-related attitudes significantly modulate demographic variation in sexual health literacy in Tasmanian university students. Sexual Health, 2017, 14, 244.	0.4	2
82	Variation within <i><scp>MBP</scp></i> gene predicts disease course in multiple sclerosis. Brain and Behavior, 2017, 7, e00670.	1.0	17
83	Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ: British Medical Journal, 2017, 356, i6583.	2.4	1,408
84	An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 395-401.	0.9	71
85	Association between human herpesvirus & mp; human endogenous retrovirus and MS onset & progression. Journal of the Neurological Sciences, 2017, 372, 239-249.	0.3	24
86	Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 453-460.	0.9	6
87	Genetic variation in the gene <i>LRP2</i> increases relapse risk in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 864-868.	0.9	21
88	Stressful life events and the risk of initial central nervous system demyelination. Multiple Sclerosis Journal, 2017, 23, 1000-1007.	1.4	14
89	The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Multiple Sclerosis Journal, 2017, 23, 1157-1166.	1.4	28
90	Non-Obese Diabetes and Its Associated Factors in an Underdeveloped Area of South China, Guangxi. International Journal of Environmental Research and Public Health, 2016, 13, 976.	1.2	5

#	Article	IF	CITATIONS
91	Anxiety, depression and fatigue at 5â€year review following <scp>CNS</scp> demyelination. Acta Neurologica Scandinavica, 2016, 134, 403-413.	1.0	47
92	Synergetic and antagonistic effects of combined calcitriol and interferon- $\hat{l}^2$ treatment on cytokine production by stimulated PBMCs. Journal of Neuroimmunology, 2016, 297, 148-155.	1.1	1
93	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	0.9	63
94	Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1204-1211.	0.9	38
95	Front-to-back & Early; dabbing wiping behaviour post-toilet associated with anal neoplasia & Early; HR-HPV carriage in women with previous HPV-mediated gynaecological neoplasia. Cancer Epidemiology, 2016, 42, 124-132.	0.8	31
96	Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1655-1664.	1.4	44
97	Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis. Neuroepidemiology, 2016, 46, 106-113.	1.1	45
98	Sexual health literacy of the student population of the University of Tasmania: results of the RUSSL Study. Sexual Health, 2015, 12, 207.	0.4	31
99	Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. BMC Nutrition, 2015, 1, .	0.6	11
100	P04.12â€Front-to-back wiping and dabbing behaviour wiping post-toilet significantly associated with anal neoplasia and hr-hpv carriage in a cohort of women with a history of an hpv-mediated gynaecological neoplasia. Sexually Transmitted Infections, 2015, 91, A100.1-A100.	0.8	0
101	P04.13â€The sexual health literacy of the student population of the university of tasmania: results of the russl study. Sexually Transmitted Infections, 2015, 91, A100.2-A100.	0.8	0
102	Admission blood glucose predicts mortality and length of stay in patients admitted through the emergency department. Internal Medicine Journal, 2015, 45, 916-924.	0.5	22
103	The epidemiology of multiple sclerosis in the Isle of Man: 2006-2011. Acta Neurologica Scandinavica, 2015, 132, 381-388.	1.0	6
104	The role of epidemiology in MS research: Past successes, current challenges and future potential. Multiple Sclerosis Journal, 2015, 21, 969-977.	1.4	37
105	Genetic variation in PBMC-produced IFN-γ and TNF-α associations with relapse in multiple sclerosis. Journal of the Neurological Sciences, 2015, 349, 40-44.	0.3	5
106	Modulating effects of <i> WT1 &lt; /i &gt; on interferon - <i> <math>\hat{l}^2</math> &lt; /i &gt; -vitamin D association in MS. Acta Neurologica Scandinavica, 2015, 131, 231-239.</i></i>	1.0	14
107	The co-occurrence of multiple sclerosis and type 1 diabetes: Shared aetiologic features and clinical implication for MS aetiology. Journal of the Neurological Sciences, 2015, 348, 126-131.	0.3	39
108	Stimulated PBMC-produced IFN-Â and TNF-Â are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 200-207.	0.9	27

#	Article	IF	Citations
109	Vascular comorbidities in the onset and progression of multiple sclerosis. Journal of the Neurological Sciences, 2014, 347, 23-33.	0.3	71
110	An adverse lipid profile is associated with disability and progression in disability, in people with MS. Multiple Sclerosis Journal, 2014, 20, 1737-1744.	1.4	123
111	Meta-Analyses to Investigate Gene-Environment Interactions in Neuroepidemiology. Neuroepidemiology, 2014, 42, 39-49.	1.1	7
112	The Scandinavian paradox revisited: Editorial comment on Berg-Hansen et al. †High prevalence and no latitude gradient of multiple sclerosis in Norwayâ€. Multiple Sclerosis Journal, 2014, 20, 1675-1677.	1.4	4
113	Higher levels of reported sun exposure, and not vitamin D status, are associated with less depressive symptoms and fatigue in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 123-131.	1.0	54
114	Idiopathic granulomatous hypophysitis: a systematic review of 82 cases in the literature. Pituitary, 2014, 17, 357-365.	1.6	73
115	The potential role of epigenetic modifications in the heritability of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 135-140.	1.4	29
116	Novel modulating effects of PKC family genes on the relationship between serum vitamin D and relapse in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 399-404.	0.9	32
117	EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. Acta Neurologica Scandinavica, 2014, 130, 328-337.	1.0	26
118	Association between multiple sclerosis risk-associated SNPs and relapse and disability – a prospective cohort study. Multiple Sclerosis Journal, 2014, 20, 313-321.	1.4	23
119	Adverse lipid profile is not associated with relapse risk in MS: Results from an observational cohort study. Journal of the Neurological Sciences, 2014, 340, 230-232.	0.3	33
120	Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Multiple Sclerosis Journal, 2013, 19, 1627-1631.	1.4	56
121	A novel method for calculating prevalence of multiple sclerosis in Australia. Multiple Sclerosis Journal, 2013, 19, 1704-1711.	1.4	18
122	Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 799-806.	1.4	51
123	Four decades of anal cancer in Tasmania, Australia: what do the case data tell us?. Sexual Health, 2012, 9, 213.	0.4	8
124	Interferon- $\hat{l}^2$ and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology, 2012, 79, 254-260.	1.5	90
125	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	1.1	166
126	Individual and Joint Action of Environmental Factors and Risk of MS. Neurologic Clinics, 2011, 29, 233-255.	0.8	63

#	Article	IF	CITATIONS
127	Role of vitamin D in multiple sclerosis: implications for disease management. Neurodegenerative Disease Management, 2011, 1, 523-536.	1.2	4
128	Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 180-187.	0.9	43
129	Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1132-1141.	0.9	556
130	Higher 25â€hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Annals of Neurology, 2010, 68, 193-203.	2.8	388
131	On-line sample preconcentration in capillary electrophoresis. Journal of Chromatography A, 2008, 1184, 504-541.	1.8	327